abstract |
The present invention is capable of directing immune cells, such as T lymphocytes, to a target antigen when the antigen binds to a polypeptide comprising a transmembrane domain derived from a T cell co-inhibitory protein, such as CTLA4 or PD-1, and A therapeutic polypeptide, such as a chimeric antigen receptor, capable of causing proliferation or killing cells displaying an antigen. The invention also relates to T lymphocytes expressing such polypeptides, and the use of such T lymphocytes to treat diseases such as cancer. |